Virbac USA veterinary site

Visit Virbac at VMX

We'll be at VMX in 2022!

Virbac is very excited to be a sponsor at the upcoming VMX Conference (Veterinary Meeting & Expo) in Orlando, Florida from January 15-19. Please stop by booth #4512 to meet the team, learn about our wonderful products, hear about exciting new product launches, and discover more about our entrance into pet nutrition:


Join us for lunch on Saturday, 1/15 from 12-1:30 pm, Hyatt Regency TUV room!

We will also be featured in the New Product Gallery:

  • Features 24 of the latest innovations at a glance, prominently displayed in the Expo Hall (live/virtual), VMX Mobile App, and

  • 3 Virbac products selected


We will sponsor several symposia on Dermatitis, Otitis, Oncology and Nutrition as well as a Saturday lunch symposium. Come join us to learn more about all the exciting things happening at Virbac. We look forward to seeing you there!

NSM Schedule.png



  1. New Product Gallery Selections



STELFONTA® (tigilanol tiglate injection): Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be  necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above  the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response  to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds  are expected to heal. Appropriate pre- and post-treatment medications must be given,  including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to  decrease the potential for severe systemic adverse reactions, including death, from mast cell  degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit

EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs: For otic (ear) use in dogs only. Contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics. Do not use in dogs with known tympanic membrane (ear drum) perforation. The safe use of EASOTIC Otic Suspension in dogs used for breeding purposes has not been evaluated. Do not administer orally.  Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product. For complete information or to obtain a package insert, contact  Virbac at 1‐800‐338‐3659, or visit 

Important Safety Information for GENESIS® (triamcinolone acetonide) Topical Spray: For use on dogs only. The use of this product in dogs less than eight pounds, less than one year of age, breeding, pregnant, or lactating has not been evaluated. In a field study with GENESIS Topical Spray, polyuria, polyphagia, aversion/discomfort, sneezing or watery eyes were reported in dogs receiving treatment. For complete information or to obtain a package insert, contact Virbac at 1-800-338-3659, or visit

CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED: For use in dogs only. Wear gloves during and wash hands after administration.  Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose of CYCLAVANCE oral solution. CYCLAVANCE oral solution should be used with caution: 1) in cases with diabetes mellitus as it may cause elevated levels of serum glucose; 2) in dogs with renal insufficiency since the effect of cyclosporine use on dogs with compromised renal function has not been studied; 3) in simultaneous administration with drugs that suppress the P-450 enzyme system, such as azoles (e.g. ketoconazole), that may lead to increased plasma levels of cyclosporine. Killed vaccines are recommended for dogs receiving CYCLAVANCE oral solution because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated. For full prescribing information, contact Virbac at 1-800-338-3659 or visit